Founders Capital Management (Texas)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,000
| Closed | -$1.48K | – | 424 |
|
|
2026
Q1 | $1.48K | Sell |
6,000
-8,000
| -57% | -$3.18K | ﹤0.01% | 368 |
|
|
2025
Q4 | $5.88K | Hold |
14,000
| – | – | ﹤0.01% | 346 |
|
|
2025
Q3 | $9.43K | Hold |
14,000
| – | – | 0.01% | 299 |
|
|
2025
Q2 | $7.58K | Hold |
14,000
| – | – | ﹤0.01% | 293 |
|
|
2025
Q1 | $9.18K | Hold |
14,000
| – | – | 0.01% | 279 |
|
|
2024
Q4 | $14.3K | Sell |
14,000
-2,000
| -13% | -$3.66K | 0.01% | 256 |
|
|
2024
Q3 | $13.9K | Buy |
16,000
+6,000
| +60% | +$4.4K | 0.01% | 266 |
|
|
2024
Q2 | $3.58K | Hold |
10,000
| – | – | ﹤0.01% | 321 |
|
|
2024
Q1 | $6.7K | Buy |
10,000
+8,000
| +400% | +$5.8K | ﹤0.01% | 304 |
|
|
2023
Q4 | $1.09K | Sell |
2,000
-2,000
| -50% | -$922 | ﹤0.01% | 361 |
|
|
2023
Q3 | $2.4K | Hold |
4,000
| – | – | ﹤0.01% | 367 |
|
|
2023
Q2 | $5.2K | Hold |
4,000
| – | – | ﹤0.01% | 341 |
|
|
2023
Q1 | $7K | Buy |
4,000
+2,000
| +100% | +$5.71K | 0.01% | 340 |
|
|
2022
Q4 | $6K | Buy |
2,000
+1,000
| +100% | +$3.88K | ﹤0.01% | 333 |
|
|
2022
Q3 | $5K | Hold |
1,000
| – | – | ﹤0.01% | 344 |
|
|
2022
Q2 | $4K | Hold |
1,000
| – | – | ﹤0.01% | 373 |
|
|
2022
Q1 | $8K | Hold |
1,000
| – | – | 0.01% | 281 |
|
|
2021
Q4 | $8K | Hold |
1,000
| – | – | 0.01% | 281 |
|
|
2021
Q3 | $9K | Buy |
+1,000
| New | +$9.88K | 0.01% | 279 |
|
Other funds holding SGMO
Founders Capital Management (Texas)'s SGMO Position: Q2 2026 in Review
Founders Capital Management (Texas) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 6,000 shares — an estimated $1.48K sold.
Founders Capital Management (Texas) first reported a position in SGMO in Q3 2021 and held it in 19 quarters. The position peaked at $14.3K in Q4 2024. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- Founders Capital Management (Texas) reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- Founders Capital Management (Texas) sold 6,000 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $1.48K.
- Founders Capital Management (Texas) first reported a position in SANGAMO THERAPEUTICS INC in Q3 2021 and held it in 19 quarters.
- Founders Capital Management (Texas)'s SANGAMO THERAPEUTICS INC position peaked at $14.3K in Q4 2024.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.